• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

No benefit in prolonged anticoagulation in cancer patients without residual venous thrombosis

byMonica ParksandDavid Wang
October 6, 2014
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Cancer patients treated with 6 months of low molecular weight heparin (LMWH) for first-time DVT with no residual clot do not benefit from an additional 6 months of treatment with LMWH.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Due to the hypercoagulable state associated with malignancy, cancer patients are at high risk for thrombotic events such as deep venous thrombosis (DVT). Although the current standard of DVT prophylaxis for cancer patients is 6 months of low-molecular weight heparin (LMWH), residual vein thrombosis (RVT) may remain after therapy. There is currently minimal evidence for the management of cancer patients with RVT following standard anticoagulation. The purpose of this trial was to determine the risk of future VTE in patients with and without RVT as well as to evaluate the effects of an additional 6 months of LMWH for patients with RVT.

The trial recruited over 340 cancer patients with a previous history of DVT. The trial randomized those with RVT to either receive additional 6 months of LMWH or discontinue their anticoagulation. After 12 months follow-up, the authors found that patients without RVT following initial LMWH therapy were at low risk for recurrent VTE. For patients with RVT, continuation of LMWH for an additional 6 months did not significantly reduce the risk of recurrent VTE compared to those who were discontinued from the LMWH, although there was a trend favoring the anticoagulation group. The results of this trial supports the conclusion that cancer patients without RVT after 6 months of LMWH are at low risk of developing VTE. However, the study is underpowered with regards to patients with RVT and the benefit of additional anticoagulation.

Click to read the study in Journal of Clinical Oncology

Click to read the accompanying editorial in Journal of Clinical Oncology

RELATED REPORTS

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Relevant Reading: Venous thromboembolism and cancer: risks and outcomes (Circulation)

In-Depth [randomized controlled trial]:  The authors of this study enrolled a total of 347 patients with active cancer and a first-time event of DVT who were treated with LMWH for 6 months. Patients with residual venous thrombosis (RVT) were then randomized to continue LMWH (n = 119) for an additional 6 months or to discontinue it (n=123), while patients without RVT stopped LMWH (n = 105). The primary end point was recurrent venous thromboembolism within 1 year following discontinuation of LMWH, while the secondary end point was major bleeding. At the conclusion of the trial, patients without RVT had a significantly lower risk of recurrent VTE compared to patients with RVT at baseline (HR: 6.0; 95% CI: 1.7 – 21.2; p < 0.005). In patients with RVT, the use of LMWH was not associated with reduced VTE current compared to patients who discontinued anticoagulation (HR: 1.37; 95% CI: 0.7-2.5; p = 0.311). There was no significant difference in major bleeding events in either group with RVT (HR: 3.78; 95% CI: 0.77 to 18.58; p = 0.102).

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: anticoagulationcancervenous thromboembolism
Previous Post

Embolization effective for treatment of upper GI bleeding in unstable patients

Next Post

Active sexting among teens related to sexual activity

RelatedReports

All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

July 2, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Next Post
Active sexting among teens related to sexual activity

Active sexting among teens related to sexual activity

Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Off-hours PICU admissions not linked to increased mortality

AAP issues new guidelines for freestanding urgent care facilities

Study reviews transition for children with special health care needs

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.